Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
about
Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft ModelsSensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraThe cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells.Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.Clonal competition with alternating dominance in multiple myeloma.Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistenceDPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia.Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.
P2860
Q28076328-BDB77FA3-341C-400E-9939-A2526E769E92Q28486093-27B30356-F36D-4DD5-BE1B-F9B72EC73AD3Q31137596-5D2A0F42-C078-4287-A4BA-AF618FE74C4AQ34136730-1861E0DA-82D4-4AE3-BD1C-F953949B06C6Q35117747-932E4BE5-041A-4DAF-A0DD-3F79CDD297D8Q36026747-AFD5F1A6-0CC4-4F70-B14C-40A188236606Q36141846-6567C019-96BD-4956-93A4-F5D654DCA4A5Q36618587-C294C214-1C00-49CE-A476-A27BAD407A2EQ36697774-3BAB71F5-6560-40EE-8DFA-F64785C97745Q36755221-CD4FFF60-6FE5-456A-8A2E-7C317330F193Q37026032-9A96B6EA-150D-49F6-8A77-5FC5AD9588FFQ37588345-D665A044-2744-482E-91D0-5B5313AFFF81Q37810967-CF8AE59F-65C5-4988-80F9-2DD57CE2A065Q37978771-87504ECA-750E-481F-99E9-D0EF140CFA39Q38113416-6528A72E-4DA7-412E-9B0E-361A16013989Q38133575-9084D892-4E7A-478C-B5DD-A02AAD3F273DQ38175466-2A776603-B986-453F-BC7E-E4A48D20A2E3Q38185576-45B08491-BEBA-4C36-B06F-8F638BD493BBQ38265115-A77758BC-58C1-46D3-BD7F-B860A60DBCB1Q38812117-A3DE04E7-D78E-41C2-8001-FD9144E5C2CDQ39172001-D6E3B2D5-4C96-4F5A-BCC3-661282147F45Q41279430-214511C5-BE6C-4582-BCFD-3E0F7FBCEA82Q44074873-C52D0EB5-655F-4A71-A1D9-F94793F4526DQ48240827-769F9D60-31BB-42B8-992C-C69FFBB673D9Q50123249-999B5E55-C972-4274-95D8-4A195CCC6FC6Q51181111-7121C806-8197-446D-8487-A6C642835F2DQ51747038-3054A673-39EC-46E5-8643-7BE17DCB22DBQ53196957-8E8A673A-B0A6-4909-8A2E-16A2630C7B15
P2860
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@ast
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@en
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@nl
type
label
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@ast
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@en
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@nl
prefLabel
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@ast
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@en
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@nl
P2093
P2860
P50
P1433
P1476
Properties of CD34+ CML stem/p ...... responses to imatinib mesylate
@en
P2093
Allen Eaves
Ashley Ringrose
Calvin Yip
Clay Smith
Connie Eaves
Donna Forrest
Emily Pang
Franck Nicolini
Heather Jorgensen
Joelle Guilhot
P2860
P304
P356
10.1182/BLOOD-2009-05-222471
P407
P577
2010-06-23T00:00:00Z